 SAN FRANCISCO, June 01, 2021 GLOBE NEWSWIRE -- Nurix Therapeutics, Inc. Nasdaq: NRIX, a biopharmaceutical company developing targeted protein modulation drugs, today announced the appointment of Clay Siegall, Ph.D., to its board of directors. Dr. Siegall is a co-founder of Seagen Inc. formerly Seattle Genetics, Inc. and serves as its president, chief executive officer, and chairman of the board. 